Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial

Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial

Background: Dipeptidyl-peptidase-4 inhibitors (iDPP-4) are pathogenically targeted drugs for diabetes mellitus type 2 (T2DM). Evogliptin is a new member of iDPP-4 class. The drug has the longest half-elimination period among the class, and its efficacy and safety as monotherapy have been already stu...

Full description

Bibliographic Details
Main Authors: Alina Y. Babenko, Anna A. Mosikian, Igor E. Makarenko, Victoriya V. Leusheva, Evgeny V. Shlyakhto
Format: Article
Language:English
Published: Endocrinology Research Centre 2018-10-01
Series:Сахарный диабет
Subjects:
idpp-4
evogliptin
sitagliptin
hba1c
Online Access:https://dia-endojournals.ru/dia/article/viewFile/9586/7367

Similar Items

Similar Items